Fluoropyrimidine

Fluoropyrimidine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Autoimmune Disease、Crohn Disease、Dermatomyositis、Hematopoietic and Lymphoid Cell Neoplasm。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Fluoropyrimidine 研究

• DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  III 期招募中荷兰NCT06275958

• Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

  I 期 / II 期招募中美国NCT07456852

• Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer

  II 期招募中中国NCT07867392

• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  II 期招募中美国加拿大中国GeorgiaNCT07069712

• A Study of NX-1607 in Adults With Advanced Malignancies

  I 期招募中美国英国NCT05107674

• Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer

  II 期招募中中国NCT07517107

• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  III 期招募中美国Argentina澳大利亚奥地利NCT06764875

• mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  III 期招募中美国Puerto RicoNCT05677490

• A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

  I 期 / II 期招募中美国NCT07818018

• Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

  II 期招募中意大利NCT06253650

• OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer

  II 期招募中丹麦NCT04680260

• Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  II 期招募中法国NCT06475352

• Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

  II 期 / III 期招募中美国中国NCT06841679

• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  I 期 / II 期招募中美国NCT06047379

• Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.

  II 期招募中RussiaNCT06888843

• Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

  I 期招募中美国NCT06065371

• JS212 Combination Therapies in Metastatic Colorectal Cancer

  II 期招募中中国NCT07503756

• Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

  III 期招募中加拿大爱尔兰挪威瑞典NCT04460352

• HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer

  II 期招募中中国NCT07621484

• D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

  III 期招募中美国中国台湾NCT06622057

• Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

  IV 期招募中美国NCT07059494

• Rectal Cancer CTC Trial

  不适用招募中CzechiaNCT07194616

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  III 期招募中美国Argentina澳大利亚奥地利NCT06731478

• Clinical Studies for the Treatment of Advanced Solid Tumors

  I 期 / II 期招募中中国NCT06825494

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。